(unaudited)
Financial performance in the nine months ended September 30, 2009
(Comparative figures for the same period last year are shown in brackets)
- Sales growth continued in Q3 and organic growth in vaccine sales was 10%
- Revenue for the first nine months of the year was DKK 1,393 million (1,308)
- Capacity costs increased by 1% to DKK 875 million (869)
- Operating profit (EBIT) for the first nine months of the year rose 50% to DKK
117 million (78)
- Operating profit before depreciation and amortization (EBITDA) was DKK 176
million (139)
- Profit for the period was DKK 82 million (63)
Adjustment of 2009 financial outlook
For the 2009 financial year, ALK forecasts organic growth in allergy vaccine
sales of approximately 10%. Operating profit (EBIT) is forecast at a minimum of
DKK 150 million. Operating profit before depreciation and amortization (EBITDA)
is forecast at a minimum of DKK 230 million.
Hørsholm, November 19, 2009
ALK-Abelló A/S
Contact:
Jens Bager, President and CEO, tel +45 4574 7576.
ALK will host a conference call for analysts and investors today at 3.30 p.m.
(CET) at which Jens Bager, President and CEO, and Jutta of Rosenborg, CFO, will
review the results. Danish participants should call in on tel +45 7026 5040
before 3.25 p.m. (CET), and international participants should call in on tel
+44 208 817 9301 before 3.25 p.m. (CET). The conference call will also be
webcast on our website: www.alk-abello.com, where the related presentation will
be available shortly before the conference call begins.
